Article
Oncology
Tsung-Yi Lin, Jeong A. Park, Alan Long, Hong-Fen Guo, Nai-Kong Cheung
Summary: The study developed a T cell-engaging bispecific antibody named BC261, which demonstrated potent cytotoxicity against EFT, prostate cancer, and canine osteosarcoma cell lines and showed superior antitumor effects in vivo. BC261 not only promoted T cell infiltration into tumors but also exhibited significant antitumor efficacy against various cancer types.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Lisa Nadal, Frederik Peissert, Abdullah Elsayed, Tobias Weiss, Thomas Look, Michael Weller, Geny Piro, Carmine Carbone, Giampaolo Tortora, Mattia Matasci, Nicholas Favalli, Riccardo Corbellari, Cesare Di Nitto, Eleonora Prodi, Chiara Libbra, Simone Galeazzi, Claudiopietro Carotenuto, Cornelia Halin, Emanuele Puca, Dario Neri, Roberto De Luca
Summary: In this study, a fully human monoclonal antibody targeting human fibroblast activation protein (FAP) was generated and shown to have tumor recognition properties. The antibody demonstrated potent antitumor activity in cancer mouse models and was well-tolerated in non-human primate safety evaluations. These results provide a rationale for future clinical translation of this fully human product.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Sayed Shahabuddin Hoseini, Mallika Vadlamudi, Madelyn Espinosa-Cotton, Hoa Tran, Yi Feng, Hong-Fen Guo, Hong Xu, Irene Cheung, Nai-Kong Cheung
Summary: This study presented data on three bispecific antibodies against the CD33 IgV and IgC domains, showing their effect on AML cell lines through in vitro binding and cytotoxicity assays. The findings support further clinical development of these BsAbs for potential first-in-human phase I clinical trial.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Karlijn de Joode, Sharon Veenbergen, Claudia Kransse, Dian Kortleve, Reno Debets, Ron H. J. Mathijssen, Arjen Joosse, Marco W. J. Schreurs, Astrid A. M. van der Veldt
Summary: A study showed that the presence of tumor-associated antibodies correlated with response to immune checkpoint inhibitor treatment in patients with metastatic melanoma. However, a new study failed to validate and extend these findings and did not identify other cancer germline antigens as predictive biomarkers of response to immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Ilene Le, Subramanian Dhandayuthapani, Jessica Chacon, Anna M. Eiring, Shrikanth S. Gadad
Summary: Prophylactic vaccination is successful in preventing infectious diseases, but therapeutic vaccination for established diseases like cancer is more challenging. Anticancer vaccines targeting tumor-associated antigens and neoantigens have shown promise. Various types of vaccines based on cellular, peptide/protein, and genomic components are in development to determine their efficacy in cancer therapy, and some have demonstrated promising results when combined with standard treatments.
Review
Immunology
Diana Corogeanu, Sandra S. Diebold
Summary: Dendritic cells are crucial for T cell activation and play a significant role in anti-tumour immune responses. Effective activation of dendritic cell function is important for successful cancer immunotherapy.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)
Review
Oncology
Hugo de Jonge, Luisa Iamele, Maristella Maggi, Greta Pessino, Claudia Scotti
Summary: Cancer is a leading cause of death worldwide, making early detection crucial for effective treatment. Auto-antibodies, circulating antibodies specific for tumor cells, have the potential to impact tumor growth and may be utilized for cancer management. However, their significance and role in cancer progression still require further research.
Review
Biochemistry & Molecular Biology
Ping Yang, Mei Meng, Quansheng Zhou
Summary: The study reveals that oncogenic CTAs are overexpressed in various cancers, promoting carcinogenesis, metastasis, and drug resistance. However, challenges in CTA-targeted cancer immunotherapy include deficient MHC-I antigen presentation, immunosuppressive cells in tumor tissues, and the tumor microenvironment reducing therapy efficacy. New strategies are proposed to overcome these barriers and develop potent immune therapeutics against cancer, as oncogenic CTAs show high tumor specificity and immunogenicity. Future breakthroughs in cancer therapy are expected with CTAs-targeted immunotherapy.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Evgenij Fiskin, Caleb A. Lareau, Leif S. Ludwig, Gokcen Eraslan, Feimei Liu, Aaron M. Ring, Ramnik J. Xavier, Aviv Regev
Summary: The study introduces a novel method called PHAGE-ATAC for simultaneous single-cell measurements of protein levels and chromatin accessibility profiles, using mitochondrial DNA-based clonal tracing. PHAGE-ATAC is utilized for multimodal analysis in primary human immune cells, sample multiplexing, intracellular protein analysis, and detection of SARS-CoV-2 spike protein. Additionally, a synthetic high-complexity phage library is constructed for selection of antigen-specific nanobodies, enabling protein detection, cell characterization, and screening with single-cell genomics.
NATURE BIOTECHNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Hongxin Liu, Zhigang Xie, Min Zheng
Summary: Cancer immunotherapy is a popular area of research, and carbon dots have shown potential as nanovectors to enhance its efficacy.
Review
Oncology
Mahmood Araghi, Reza Mannani, Ali Heidarnejad Maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi, Reza Akhavan-Sigari
Summary: Lung cancer is the leading cause of cancer-related death globally, and significant advancements have been made in the last decade in diagnosing and treating NSCLC through molecular translational research. Targeted therapy, specifically aimed at specific genes, proteins, or the tumor microenvironment, has shown the most successful outcomes in NSCLC treatment. Efforts are currently focused on improving targeted therapy to enhance cancer treatment outcomes and patient quality of life. This updated study provides a comprehensive discussion on tumor target antigens and targeted therapy-related agents, along with a summary of available clinical trial studies for NSCLC patients.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Lena Immisch, George Papafotiou, Oliver Popp, Philipp Mertins, Thomas Blankenstein, Gerald Willimsky
Summary: The H3.3K27M mutation is unlikely to be a suitable target for cancer immunotherapy due to insufficient epitope processing and/or amount for recognition by HLA-A*02:01 restricted CD8(+) T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Chemistry, Multidisciplinary
Yang Bo, Hua Wang
Summary: Cancer immunotherapies, including therapeutic cancer vaccines, have revolutionized cancer treatment. However, the limited efficacy of cancer vaccines, especially for immunologically cold solid tumors, remains a challenge. In situ cancer vaccines, particularly biomaterials-based vaccines, have emerged as a promising approach to address this challenge by generating endogenous antigens directly from tumors. This review provides an overview of biomaterials-based in situ cancer vaccines, discussing their design criteria and potential applications.
ADVANCED MATERIALS
(2023)
Article
Oncology
Caroline A. Nebhan, Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, Neha Debnath, Anwaar Saeed, Maluki Radford, Asrar Alahmadi, Akiva Diamond, Christopher Hoimes, Nikhil Ramaiya, Carolyn J. Presley, Dwight H. Owen, Sarah Abou Alaiwi, Amin Nassar, Biagio Ricciuti, Giuseppe Lamberti, Melissa Bersanelli, Chiara Casartelli, Sebastiano Buti, Paolo Marchetti, Raffaele Giusti, Marco Filetti, Vito Vanella, Domenico Mallardo, Shravanti Macherla, Tamara A. Sussman, Andrea Botticelli, Domenico Galetta, Annamaria Catino, Pamela Pizzutilo, Carlo Genova, Maria Giovanna Dal Bello, Foteini Kalofonou, Ella Daniels, Paolo A. Ascierto, David J. Pinato, Toni K. Choueiri, Douglas B. Johnson, Thomas U. Marron, Yinghong Wang, Abdul Rafeh Naqash
Summary: An international multicenter retrospective study showed that treatment with ICIs may be effective and generally well tolerated among older patients with cancer, although ICI discontinuation due to irAEs was more frequent with increasing age.
Review
Immunology
Michael S. Lee, Tonya J. Webb
Summary: Cancer immunotherapy aims to harness the immune system's power to fight tumors while avoiding the side effects of traditional chemotherapy. iNKT cells, a type of innate immune cell, have gained recognition for their potential in cancer immunotherapy. They recognize lipid antigens presented on the MHC I-like molecule CD1d, representing a unique feature of tumor cells that can be exploited by iNKT cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Bryan D. Choi, Marcela V. Maus, Carl H. June, John H. Sampson
CLINICAL CANCER RESEARCH
(2019)
Article
Oncology
Carter M. Suryadevara, Rupen Desai, S. Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, David J. Snyder, James E. Herndon, Patrick Healy, Elizabeth A. Reap, Gary E. Archer, Peter E. Fecci, John H. Sampson, Luis Sanchez-Perez
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
William Tomaszewski, Luis Sanchez-Perez, Thomas F. Gajewski, John H. Sampson
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
Kenneth Aldape, Kevin M. Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R. Gilbert, Nicholas Gottardo, David H. Gutmann, Darren Hargrave, Eric C. Holland, David T. W. Jones, Johanna A. Joyce, Pamela Kearns, Mark W. Kieran, Ingo K. Mellinghoff, Melinda Merchant, Stefan M. Pfister, Steven M. Pollard, Vijay Ramaswamy, Jeremy N. Rich, Giles W. Robinson, David H. Rowitch, John H. Sampson, Michael D. Taylor, Paul Workman, Richard J. Gilbertson
NATURE REVIEWS CLINICAL ONCOLOGY
(2019)
Article
Oncology
Teilo H. Schaller, David J. Snyder, Ivan Spasojevic, Patrick C. Gedeon, Luis Sanchez-Perez, John H. Sampson
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Multidisciplinary Sciences
Patrick C. Gedeon, Michael A. Streicker, Teilo H. Schaller, Gary E. Archer, Micheal P. Jokinen, John H. Sampson
Review
Oncology
Kelly M. Hotchkiss, John H. Sampson
Summary: GBM is difficult to eradicate with immunotherapy and chemotherapy, and different doses and timing of chemotherapy may affect tumor eradication efficacy.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Patrick C. Gedeon, Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi, John H. Sampson
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2020)
Article
Multidisciplinary Sciences
Yaoying Wu, Hanning Wen, Zachary J. Bernstein, Kelly M. Hainline, Tykia S. Blakney, Kendra L. Congdon, David J. Snyder, John H. Sampson, Luis Sanchez-Perez, Joel H. Collier
Summary: The study demonstrates the potential clinical benefit of vaccine-induced antibody responses for tumor treatments when combined with simultaneous CD8(+) and CD4(+) responses, using a nanofiber vaccine design approach. Additionally, the study highlights the importance of supramolecular nanomaterials in developing multiepitope cancer vaccines.
Review
Surgery
Seshiru Nakazawa, Toshiteru Nagashima, Natsuko Kawatani, Patrick C. Gedeon, Ariadne K. DeSimone, Hitoshi Igai, Takayuki Kosaka, Ken Shirabe
Summary: The lung anatomy has been traditionally described through cadaveric studies and surgical findings. However, the development of computed tomography (CT) and three-dimensional (3D) imaging techniques has allowed for a more intuitive reconstruction and understanding of lung anatomy. The adoption of 3D-CT imaging technology has led to various anatomical studies, contributing to the development of new classification systems, providing useful surgical perspectives, and enabling focused analysis of specific anatomical features. Additionally, 3D imaging offers enhanced simulation, improved surgical safety, educational utility, and the ability to conduct large-scale anatomical studies more efficiently. Therefore, the continuous advancement of 3D imaging analysis and innovative methodologies will further refine our knowledge of lung anatomy and enhance the safety and effectiveness of surgical resections.
VIDEO-ASSISTED THORACIC SURGERY
(2023)
Meeting Abstract
Oncology
Kirit Singh, Patrick Gedeon, Teilo Schaller, David Snyder, Mustafa Khasraw, John Sampson
Meeting Abstract
Oncology
Teilo Schaller, Matthew Foster, Ivan Spasojevic, Patrick Gedeon, Luis Sanchez-Perez, John Sampson
Meeting Abstract
Oncology
Patrick C. Gedeon, Carter M. Suryadevara, Bryan D. Choi, John H. Sampson
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Review
Oncology
John H. Sampson, Michael D. Gunn, Peter E. Fecci, David M. Ashley
NATURE REVIEWS CANCER
(2020)